The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus

Clinical Rheumatology

Volumn 29, Issue 7, 2010, Pages 771-775

  Weng, Meng Yu ^a   Weng, Chia Tse ^a   Liu, Ming Fei ^a  

^a Medical College and Hospital ^*  (Taiwan)

Author keywords

Lupus nephritis; Mycophenolate mofetil; Steroids; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY BIOPSY; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DOSE CALCULATION; DOSE RESPONSE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; STANDARDS;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TAIWAN; TREATMENT OUTCOME;

EID: 77956262334     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1403-9     Document Type: Article

References (33)

1. Gladman DD, Urowitz MB (2002) Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois' lupus erythematosus, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1255-1273
2. Yee CS, Gordon C, Dstal C et al (2004) EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63:525-529
3. Falk RJ (2000) Treatment of lupus nephritis-a work in progress. N Engl J Med 343:1182-1183
4. Gourley MF, Austin HA III, Sott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 125:549-557
5. Korbet SM, Lewis EJ, Shwartz MM et al (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904-914
6. Mok CC, Yee KY, Sdney Tang, Leung CY et al (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559-2568
7. Ioannidis JPA, Boki KA, Ktsorida EM et al (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258-264
8. Austin H, Klippel J, Blow J et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619
9. Valeri A, Radhakrishnan J, Etes D et al (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42:71-78
10. Boumpas DT, Austin HA III, vughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
11. Eugui EM, Allison AC (1993) Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 685:309-329
12. Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85-118
13. Borba EF, Guedes LK, Cristmann RB et al (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26:1078-1083
14. Chan TM, Li FK, Tng CSO et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156-1162
15. Chan TM, Tse KC, Tng CSO, Mok MY et al (2005) Hong Kong Nephrology Study G Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076-1084
16. Dooley MA, Cosio FG, Nchman PH et al (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833-839
17. Adu D, Cross J, Jyne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203-208 (Pubitemid 32410078)
18. Neylan JF (1997) Immunosuppressive therapy in high-risk trasplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 64:1277-1282
19. Dooley MA, Hogan S, Jnnette C et al (1997) Cyclophosphamide therapy for lupus nephritis: poor renal suvival in black americans. Kidney Int 51:1188-1195
20. Tan EM, Cohen AS, Fies JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
21. Weening JJ, D'Agati VD, Shwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241-250
22. Ginzler EM, Aranow C (2005) Mycophenolate mofetil in lupus nephritis. Lupus 14:59-64
23. Elyan M, Ballou S (2009) The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin Rheumatol
24. Gaubitz M, Schorat A, Shotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731-736
25. Ginzler EM, Dooley MA, Aanow C (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219-2228
26. Cross J, Dwomoa A, Adrews P et al (2005) Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 100: c92-100
27. Karim MY, Alba P, Cadrado MJ et al (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876-882
28. Denton MD, Galvanek EG, Sngh A, Sayegh MH (2001) Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. American Journal of Transplantation 1:288-292
29. Chan TM, Li FK, Tng CS, Wong RW et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156-1162
30. Appel GB, Contreras G, Doley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103-1112
31. Zhu B, Chen N, Ln Y et al (2007) Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22:1933-1942
32. Bijl M, Horst G, Botsma H et al (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62:534-539
33. Kingdon EJ, McLean AG, Pimenou E et al (2001) The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10:606-611